ReviewThe Journal of allergy and clinical immunology2020
Emerging therapies for eosinophilic esophagitis.
Review in The Journal of allergy and clinical immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- Effect of budesonide oral suspension on dysphagia and esophageal inflammation in eosinophilic esophagitis: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- A meta-analysis on randomized controlled trials of treating eosinophilic esophagitis with budesonide.Annals of medicine · 2022Pooled it
- Molecular Characterization of Non-Specific Esophagitis Reveals a Distinct Non-Eosinophilic Phenotype With Fibrotic Traits.Allergy · 2026Article
- Advancing the understanding of eosinophilic esophagitis: From pathogenesis to novel therapies.World journal of gastrointestinal pathophysiology · 2026Review
- Blind-Ending Esophageal Fistula Complicating Eosinophilic Esophagitis: Case Report and Up-to-Date Strategy from Diagnosis to Therapy.Diagnostics (Basel, Switzerland) · 2026Article
- [Eosinophilic esophagitis].Innere Medizin (Heidelberg, Germany) · 2025Review
- Real-world-data on efficacy and safety of topical budesonide therapy (orodispersible tablet) in induction and maintenance therapy in adult patients with active eosinophilic esophagitis.Therapeutic advances in gastroenterology · 2025Article
- Off-Label Use of Monoclonal Antibodies for Eosinophilic Esophagitis in Humans: A Scoping Review.Biomedicines · 2024Article
- Patient-reported symptoms and burden of eosinophilic esophagitis: evidence from real-world clinical practice.BMC gastroenterology · 2024Article
- Eosinophilic Esophagitis: What's in a Name?Digestive diseases and sciences · 2024Article
- A retrospective real-world study on the safety and efficacy of budesonide orodispersible tablets for the induction therapy of eosinophilic oesophagitis.Therapeutic advances in gastroenterology · 2024Article
- High prevalence of response to PPI treatment in children and adolescents with eosinophilic esophagitis in southern Brazil.Frontiers in allergy · 2024Article
- Successful use of dupilumab for egg-induced eosinophilic gastroenteritis with duodenal ulcer: a pediatric case report and review of literature.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2023Article
- Emotional Journey of Patients with Eosinophilic Esophagitis.Advances in therapy · 2023Article
- Assessment of the Severity and the Remission Criteria in Eosinophilic Esophagitis.Biomedicines · 2023Review
- Higher Body Mass Index Is Associated With Decreased Treatment Response to Topical Steroids in Eosinophilic Esophagitis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023Article
- Pre-treatment differential correlation of gene expression and response to topical steroids in eosinophilic esophagitis.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2023Article
- Signals from the TAFA4-PTEN-PU.1 axis alleviate nasal allergy by modulating the expression of FcεRI in mast cells.Clinical and experimental immunology · 2023Article
- Eosinophilic Gastrointestinal Diseases: The Pathogenesis, Diagnosis, and Treatment.Internal medicine (Tokyo, Japan) · 2023Article
- EoE behaves as a unique Th2 disease: a narrative review.Translational gastroenterology and hepatology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
Abstract
Despite advances in the pathologic understanding of eosinophilic esophagitis (EoE), as of yet, no single agent has been approved by the US Food and Drug Administration to treat EoE. Off-label, EoE is currently treated by using the 3 Ds: drugs (particularly swallowed topical corticosteroids), dietary restriction, and endoscopic dilation. In the recent past, considerable progress in terms of EoE treatment has been made: (1) new EoE-specific steroid formulations optimizing mucosal deposition have been developed, which has culminated in recent approval of a budesonide effervescent tablet in Europe; (2) biologics used for other T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.